Shousen Hu1, Yongliang Yuan2,3, Zhizhen Song2,3, Dan Yan2,3, Xiangzhen Kong4,5. 1. Department of Otolaryngology Head and Neck Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. 2. Department of Pharmacy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. 3. Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou, China. 4. Department of Pharmacy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Chinakongxiangzhen118@126.com. 5. Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou, Chinakongxiangzhen118@126.com.
Abstract
BACKGROUND/AIMS: Drug resistance remains a main obstacle to the treatment of non- small cell lung cancer (NSCLC). The aim of this study was to identify the expression profiles of microRNAs (miRNAs) in drug-resistant NSCLC cell lines. METHODS: The expression profiles of miRNAs in drug-resistant NSCLC cell lines were examined using miRNA sequencing, and the common dysregulated miRNAs in these cell lines were identified and analyzed by bioinformatics methods. RESULTS: A total of 29 upregulated miRNAs and 36 downregulated miRNAs were found in the drug-resistant NSCLC cell lines, of which 26 upregulated and 36 downregulated miRNAs were found to be involved in the Ras signaling pathway. The expression levels, survival analysis, and receiver operating characteristic curve of the dysregulated miRNAs based on The Cancer Genome Atlas database for lung adenocarcinoma showed that hsa-mir-192, hsa-mir-1293, hsa-mir-194, hsa-mir-561, hsa-mir-205, hsa-mir-30a, and hsa-mir-30c were related to lung cancer, whereas only hsa-mir-1293 and hsa-mir-561 were not involved in drug resistance. CONCLUSION: The results of this study may provide novel biomarkers for drug resistance in NSCLC and potential therapies for overcoming drug resistance, and may also reveal the potential mechanisms underlying drug resistance in this disease.
BACKGROUND/AIMS: Drug resistance remains a main obstacle to the treatment of non- small cell lung cancer (NSCLC). The aim of this study was to identify the expression profiles of microRNAs (miRNAs) in drug-resistant NSCLC cell lines. METHODS: The expression profiles of miRNAs in drug-resistant NSCLC cell lines were examined using miRNA sequencing, and the common dysregulated miRNAs in these cell lines were identified and analyzed by bioinformatics methods. RESULTS: A total of 29 upregulated miRNAs and 36 downregulated miRNAs were found in the drug-resistant NSCLC cell lines, of which 26 upregulated and 36 downregulated miRNAs were found to be involved in the Ras signaling pathway. The expression levels, survival analysis, and receiver operating characteristic curve of the dysregulated miRNAs based on The Cancer Genome Atlas database for lung adenocarcinoma showed that hsa-mir-192, hsa-mir-1293, hsa-mir-194, hsa-mir-561, hsa-mir-205, hsa-mir-30a, and hsa-mir-30c were related to lung cancer, whereas only hsa-mir-1293 and hsa-mir-561 were not involved in drug resistance. CONCLUSION: The results of this study may provide novel biomarkers for drug resistance in NSCLC and potential therapies for overcoming drug resistance, and may also reveal the potential mechanisms underlying drug resistance in this disease.
Authors: Lauren MacDonagh; Michael F Gallagher; Brendan Ffrench; Claudia Gasch; Steven G Gray; Marie Reidy; Siobhan Nicholson; Niamh Leonard; Ronan Ryan; Vincent Young; John J O'Leary; Sinead Cuffe; Stephen P Finn; Kenneth J O'Byrne; Martin P Barr Journal: Transl Lung Cancer Res Date: 2021-04
Authors: Fengfeng Wang; Fei Meng; Sze Chuen Cesar Wong; William C S Cho; Sijun Yang; Lawrence W C Chan Journal: Ther Adv Respir Dis Date: 2020 Jan-Dec Impact factor: 4.031
Authors: Dominik A Barth; Ondrej Slaby; Christiane Klec; Jaroslav Juracek; Rares Drula; George A Calin; Martin Pichler Journal: Cancers (Basel) Date: 2019-10-17 Impact factor: 6.639